Skip to Content

Jevtana Approval History

FDA Approved: Yes (First approved June 17, 2010)
Brand name: Jevtana
Generic name: cabazitaxel
Dosage form: Injection
Company: Sanofi
Treatment for: Prostate Cancer

Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.

Development History and FDA Approval Process for Jevtana

DateArticle
Jun 17, 2010Approval Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide